Heartbeats and Genomes: How Yale Helped Create Modern Fetal Medicine

Modern fetal medicine is built on a simple but once-radical idea: that the fetus is a patient whose health can be observed, measured, and protected before birth. That idea did not emerge all at once. It developed over decades through a series of breakthroughs that transformed obstetrics from a field guided largely by observation and intuition into one grounded in continuous data, imaging, genetics, and ethics.

Many of those breakthroughs trace back to Yale.

From the first continuous fetal heart monitoring system to the early clinical use of ultrasound, prenatal genetic diagnosis, and ethical frameworks for fetal research, Yale physicians helped lay the foundations of modern fetal medicine—moving care earlier in pregnancy and making the invisible increasingly visible.

Until the mid-20th century, physicians had limited ways to assess fetal well-being during pregnancy and labor. During childbirth, fetal heart rate was checked intermittently with a stethoscope—if it could be distinguished at all from the mother’s heartbeat or the ambient noise of the delivery room. During contractions, when the fetus was under the greatest stress, assessment was especially difficult.

If a fetus was in distress, clinicians often did not know until it was too late to intervene. Obstetric care relied heavily on experience, pattern recognition, and what Yale physician Orvan W. Hess, MD, would later describe as a “watch and wait and pray” approach.

That uncertainty became the catalyst for change.

In the 1950s, two Yale physicians—Hess and Edward H. Hon, MD, both in the Department of Obstetrics, Gynecology, and Reproductive Sciences—set out to solve a fundamental problem: how to continuously monitor fetal well-being during labor.

Their solution was the world’s first continuous fetal heart monitor, a large electrocardiographic device capable of translating the fetal heartbeat into a continuous paper tracing. Introduced in 1957 and reported in Science, the monitor allowed clinicians to establish a baseline fetal heart rate and detect changes associated with distress in real time.

Fetal electrocardiograms had been recorded earlier, but primarily to confirm that a fetus was alive. Hess and Hon expanded the purpose of the technology. Their system made it possible to assess how a fetus responded to labor itself—and to intervene when necessary.

“It was a huge change,” Joshua Copel, MD, professor of obstetrics, gynecology, and reproductive sciences and of pediatrics at Yale School of Medicine, later told The New York Times. “It allowed us to get an initial understanding of what was going on for the fetus during labor.”

The invention marked a turning point. For the first time, the fetus could be monitored continuously as a physiologic patient.

The fetal heart monitor transformed care during labor. The next challenge was extending meaningful fetal assessment earlier—well before delivery. That work took shape at Yale in the 1960s and 1970s, as physicians began to pair emerging imaging technologies with advances in genetics and laboratory science.

Among the key figures in this next phase was John C. Hobbins, MD, who trained at Yale and helped pioneer the clinical use of ultrasound in obstetrics. At a time when ultrasound was still experimental, Yale clinicians recognized its potential to move fetal assessment beyond indirect signals and into direct visualization.

Ultrasound made it possible to evaluate fetal growth, anatomy, and development over time. It allowed clinicians to identify structural abnormalities, estimate gestational age more accurately, and monitor pregnancies in ways that had never before been possible.

Like fetal heart monitoring, ultrasound changed obstetrics by turning uncertainty into information—and by shifting attention to the fetus long before labor began.

Visualization alone, however, could not answer every question. As ultrasound revealed abnormalities, clinicians needed ways to understand their underlying causes.

That need brought genetics into obstetric care.

Beginning in the 1970s, Yale pediatrician Maurice J. Mahoney, MD—who held appointments in pediatrics, genetics, and obstetrics and gynecology—became a central figure in the development of prenatal diagnosis at Yale. Working closely with obstetric colleagues, including Hobbins, Mahoney helped integrate genetic counseling and laboratory analysis directly into prenatal care.

Over the next decade, Mahoney, Hobbins, and colleagues developed and refined diagnostic techniques that were unprecedented at the time. They were the first to use fetoscopy, which involved inserting a small fiber-optic camera through the uterine wall to directly visualize the fetus and placenta, to collect fetal blood for diagnostic evaluation—work that drew referrals from across the United States and the globe.

As ultrasound technology advanced, these procedures evolved into less invasive, real-time ultrasound-guided sampling of umbilical cord blood, reducing risk while expanding diagnostic capability.

These approaches enabled the earliest prenatal diagnoses of genetic and congenital conditions, including hemoglobinopathies, skeletal dysplasias, and neuromuscular disorders such as muscular dystrophy. They also reinforced a profound shift in thinking: the fetus was not only visible, but diagnosable—an identifiable patient whose condition could be understood before birth.

Yale’s influence on fetal and reproductive medicine did not stop at technology and diagnosis. The institution also helped define how clinicians are trained.

Yale faculty, including Leon Speroff, Robert Glass, and Nathan Kase, co-authored one of the most influential textbooks in the discipline of reproductive endocrinology, a field intimately connected to prenatal biology, fertility, and hormonal regulation during pregnancy. Clinical Gynecologic Endocrinology and Infertility, first published in 1973, has been used to train generations of physicians around the world, providing clear, authoritative guidance on female reproductive physiology, endocrinology, and clinical care.

This contribution ensured that Yale’s innovative ideas did not remain local to New Haven—they became part of the core curriculum for obstetricians, gynecologists, and reproductive medicine specialists globally.

As prenatal diagnosis became more powerful—and more invasive—new ethical questions emerged. How should fetal research be conducted? What protections were needed for both the fetus and the pregnant patient? How could innovation proceed without compromising trust or safety?

Mahoney recognized early that scientific progress and ethical oversight had to advance together. He became deeply involved in the governance of human subjects research, serving on Yale’s Human Investigation Committee and later as its executive director. His expertise extended nationally, including service as a consultant to federal commissions and advisory committees focused on fetal research and gene therapy.

This emphasis on ethics became a defining feature of Yale’s approach to fetal medicine. Innovation was paired with institutional responsibility—an approach that remains central to the field today.

By the late 20th century, advances pioneered at Yale—including continuous monitoring, ultrasound imaging, prenatal genetics, and ethical oversight—had coalesced into a new model of care that treated the fetus as a patient.

That legacy continues today through programs such as the Yale Fetal Care Center, where multidisciplinary teams bring together expertise in obstetrics, pediatrics, surgery, genetics, imaging, and ethics to care for complex pregnancies. While the tools have evolved, the goal remains the same: earlier diagnosis, clearer insight, and coordinated care for both mother and fetus.

From heart rate tracings to ultrasound images, genetic analysis, and the textbooks that trained generations of clinicians, Yale physicians helped redefine what was possible in obstetric care. That trajectory—from heartbeats to genomes—helped shape modern fetal medicine and continues to influence how care is delivered today.